Clinical Trial Update: Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing rosiglitazone to a sulfonylurea in patients with heart disease and type 2 diabetes assessed progression of atherosclerosis; results ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Ischemic Heart Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Rosiglitazone (rosiglitazone)
• Sulfonylurea (unspecified comparator)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Atherosclerosis | Phase 3 | Status: COMPLETED | Results posted: 2010-03-31